Welcome to our dedicated page for Dentsply Sirona news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on Dentsply Sirona stock.
DENTSPLY SIRONA Inc. (Nasdaq: XRAY) regularly issues news and updates that shed light on its role as the world’s largest diversified manufacturer of professional dental products and technologies. Company press releases cover topics such as strategic partnerships, leadership changes, financial results and portfolio decisions, giving investors and dental professionals insight into how the business is evolving.
Recent news has highlighted Dentsply Sirona’s focus on connected dentistry and technology-enabled solutions. The company has announced expanded and renewed distribution partnerships in the United States that provide access to its dental technology portfolio, including systems and imaging solutions referenced in those agreements. These announcements emphasize integrated ecosystems that connect devices, software and services from scanning through design and manufacturing workflows.
News items also address corporate strategy and performance, including quarterly financial results and the introduction of a Return-to-Growth action plan. In these updates, Dentsply Sirona outlines priorities such as putting customers at the center, strengthening the U.S. business, and evolving operations to support innovation and training. Leadership appointments in commercial, finance and regional roles are frequently reported, reflecting the company’s efforts to align its organization with these priorities.
Other press releases describe decisions about the Wellspect Healthcare business, dividend declarations, participation in investor conferences and the conclusion of an SEC Division of Enforcement investigation without enforcement action. Together, these news items provide a detailed view of how Dentsply Sirona manages its portfolio, governance and capital allocation. Readers interested in XRAY can use this news feed to follow developments in connected dentistry, strategic partnerships, governance actions and financial communications from the company.
Dentsply Sirona (Nasdaq: XRAY) has announced a quarterly cash dividend declaration by its Board of Directors. The company will pay $0.16 per share of common stock, which indicates an annual rate of $0.64 per share. Shareholders who are holders of record as of December 27, 2024, will receive the dividend payment on January 10, 2025.
Dentsply Sirona (Nasdaq: XRAY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Interested parties can access both the live audio webcast and replay through the Investors section of Dentsply Sirona's website at investor.dentsplysirona.com.
Dentsply Sirona (Nasdaq: XRAY) has appointed Herman V. Cueto as Interim Chief Financial Officer, effective immediately. Cueto brings over 20 years of experience in healthcare finance leadership. He will oversee the finance organization while the company conducts its search for a permanent CFO. CEO Simon Campion expressed confidence in Cueto's financial acumen, operational expertise, and understanding of the global healthcare sector to help execute strategic priorities during this transition period.
Dentsply Sirona (XRAY) reported Q3 2024 results with net sales of $951 million, up 0.5% year-over-year, with organic sales growth of 1.3%. The company posted a GAAP net loss of ($494) million, or ($2.46) per share, including a non-cash goodwill impairment charge of ($495) million. Adjusted EPS was $0.50, slightly up from $0.49 in Q3 2023. Due to market pressures in U.S. equipment and challenges with Byte, the company revised its FY24 outlook, now expecting organic sales decline of (3.5%) to (2.5%) and adjusted EPS of $1.82 to $1.86.
Dentsply Sirona (Nasdaq: XRAY) has announced a conference call and live webcast scheduled for October 25, 2024, at 9:00 am ET to discuss their Byte Aligner business. Interested participants can register for the call through the provided registration link. A replay of the webcast will be made available in the Investors section of the company's website after the call concludes.
Dentsply Sirona (XRAY) has voluntarily suspended sales and marketing of its Byte Aligners and Impression Kits while reviewing regulatory requirements in consultation with the FDA. The company reports preliminary Q3 2024 net sales of approximately $951 million with adjusted EPS expected between $0.49-$0.51. The company expects to record non-cash goodwill impairment charges of $450-$550 million for its Orthodontic Aligner Solutions and Implants & Prosthetic Solutions units, driven by state regulatory impacts on Byte business and weakened demand with competitive pricing pressures.
Dentsply Sirona, the world's largest manufacturer of professional dental products and technologies, has published its 2023 Sustainability Report. The report showcases strong progress in the company's sustainability strategy 'BEYOND: Taking Action for a Brighter World', with several goals achieved ahead of the 2025 timeframe.
Key highlights include:
- 47% reduction in Scope 1 and 2 GHG emissions intensity compared to 2019
- 29% reduction in water withdrawal intensity compared to 2019
- Enabled over 5.5 million smiles in 2023, contributing to more than 16.8 million smiles since 2021
- Achieved total average gender pay parity across the global workforce
- 54% of global hires in 2023 were diverse
- Hosted over 9,200 educational courses for customers in over 80 countries
- Achieved a top decile injury and illness prevention rate of 0.17
The company remains committed to its goal of Net Zero in Scope 1-3 carbon emissions by 2050 and continues to drive sustainable change within the dental industry through partnerships and initiatives.
Dentsply Sirona (Nasdaq: XRAY) has announced an upcoming investor conference call and live webcast scheduled for Thursday, November 7, 2024, at 8:30 am ET. The purpose of this event is to review the company's third quarter financial results.
Key details include:
- A presentation related to the call will be available on the Investors section of Dentsply Sirona's website.
- Investors can access the live webcast through the company's investor relations webpage.
- Those planning to participate in the call are required to register through a provided link.
- A webcast replay of the conference call will be made available on the company's website after the event.
This announcement demonstrates Dentsply Sirona's commitment to transparency and shareholder communication regarding its financial performance.
Dentsply Sirona (Nasdaq: XRAY) has introduced Primescan 2, a cloud-native intraoral scanning solution powered by DS Core. This wireless scanner can operate on any internet-connected device, offering improved workflow efficiency and extended treatment capabilities compared to previous models. Key benefits include:
- Hardware-independence: Works on any device with an internet browser
- Versatility: Wireless and portable
- Simple handling: Sleeker design with narrower tip
- Fast workflow: Full arch scan in less than 1 minute
- Cloud storage: Reduces need for additional scan storage costs
- Always up-to-date: Automatic software updates via DS Core
Primescan 2 aims to enhance patient experience, support practice growth, and deliver simplicity, efficiency, and versatility to dental professionals.
Dentsply Sirona (Nasdaq: XRAY) has announced its participation in two upcoming investor conferences. The company will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 9:15 am ET, and the Baird Global Healthcare Conference on September 10, 2024, at 9:40 am ET.
Investors and other interested parties can access live audio webcasts and audio webcast replays of these presentations through the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. This participation in major healthcare conferences demonstrates Dentsply Sirona's commitment to engaging with investors and sharing insights about the company's performance and outlook in the dental industry.